This once-weekly injection is intended for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one comorbidity
Inhibition of Sugar Release: By blocking a hormone that signals the liver to release sugar into the bloodstream, the peptide helps maintain stable blood sugar levels and reduces cravings for sugary foods
[DOI] [PMC free article] [PubMed] [Google Scholar] Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, Rosati G
Compounded Semaglutide + Tirzepatide injection, provider-titrated
Finally, oral administration of the nonnutritive sweetener, Dallulose, was found to selectively increase active GLP1 in the hepatic portal vein without altering the levels of other gut hormones (Iwasaki et al., 2018)